Shaping the future of clinical trials through strategic foresight.

IF 2.4 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Clinical Trials Pub Date : 2026-06-01 Epub Date: 2026-02-26 DOI:10.1177/17407745251414680
Sharon Lee, Jeff McIntyre, Tracey Robertson, Kimberley Kallsen, Martin Bauer, Rossana Berardi, Christian Boisvert-Huneault, Emmanuelle Clerisme-Beaty, Christopher P Denton, Eric Fakra, Jan Geissler, David Goldstein, Kazuo Hasegawa, Manya Lind, Patricia LoRusso, Keith Perry, Claas Röhl, Jose Francisco Kerr Saraiva, Nidhi Swarup, Aron Szpisjak, Allan Flyvbjerg
{"title":"Shaping the future of clinical trials through strategic foresight.","authors":"Sharon Lee, Jeff McIntyre, Tracey Robertson, Kimberley Kallsen, Martin Bauer, Rossana Berardi, Christian Boisvert-Huneault, Emmanuelle Clerisme-Beaty, Christopher P Denton, Eric Fakra, Jan Geissler, David Goldstein, Kazuo Hasegawa, Manya Lind, Patricia LoRusso, Keith Perry, Claas Röhl, Jose Francisco Kerr Saraiva, Nidhi Swarup, Aron Szpisjak, Allan Flyvbjerg","doi":"10.1177/17407745251414680","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Global megatrends, including population growth, interconnectedness and artificial intelligence, are already shaping the clinical trials industry, and will do so for decades to come. Innovations from technology companies, greater collaboration with patients and caregivers, and increased diversity in clinical trials could transform clinical trials of the future. However, the industry has typically been slow to adopt new technologies, and certain barriers could stifle innovation and allow health inequalities to persist. Our aim was to explore the trends shaping clinical trials and identify initiatives that can be started now to move toward a future where patients are actively involved in clinical trial design and decision-making, and technologies like artificial intelligence are integrated responsibly and ethically into clinical trials.</p><p><strong>Methods: </strong>We used strategic foresight methodology to explore the trends that will shape the future of clinical trials and how the trajectory of these trends could lead to different future scenarios We then identified initiatives that could help us move toward our desired scenario.</p><p><strong>Results: </strong>We identified four possible scenarios for the future of clinical trials based on two key trends: data sharing and adaptation of regulatory frameworks. While the future will see collection of large amounts of data from different sources, such as databases and wearable devices, their usefulness could be limited if data remain in silos, limited by strict regulations and a lack of trust in data privacy. Alternatively, data may be integrated more efficiently into clinical trials if regulators adapt proactively to new technologies and patients are empowered to take control over their data, for example. We identified initiatives that can be started now to achieve our vision. Pharmaceutical companies, academic researchers, non-governmental organizations (including patient organizations), regulatory authorities, policymakers, technology companies and innovative service providers must join forces and work on initiatives to integrate technology into trials, enable data sharing, harmonize regulations across regions, co-design trials with patients and caregivers, strengthen decentralized trial capabilities and promote diversity in trials.</p><p><strong>Conclusion: </strong>Through a collaborative cross-industry effort that prioritizes proactive patient involvement and responsible use of technology, we can shape a clinical trial ecosystem that is inclusive, ethical and ready for the future. We urge all stakeholders to act now on these initiatives to positively influence the future of clinical trials.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"309-319"},"PeriodicalIF":2.4000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13242527/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745251414680","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aims: Global megatrends, including population growth, interconnectedness and artificial intelligence, are already shaping the clinical trials industry, and will do so for decades to come. Innovations from technology companies, greater collaboration with patients and caregivers, and increased diversity in clinical trials could transform clinical trials of the future. However, the industry has typically been slow to adopt new technologies, and certain barriers could stifle innovation and allow health inequalities to persist. Our aim was to explore the trends shaping clinical trials and identify initiatives that can be started now to move toward a future where patients are actively involved in clinical trial design and decision-making, and technologies like artificial intelligence are integrated responsibly and ethically into clinical trials.

Methods: We used strategic foresight methodology to explore the trends that will shape the future of clinical trials and how the trajectory of these trends could lead to different future scenarios We then identified initiatives that could help us move toward our desired scenario.

Results: We identified four possible scenarios for the future of clinical trials based on two key trends: data sharing and adaptation of regulatory frameworks. While the future will see collection of large amounts of data from different sources, such as databases and wearable devices, their usefulness could be limited if data remain in silos, limited by strict regulations and a lack of trust in data privacy. Alternatively, data may be integrated more efficiently into clinical trials if regulators adapt proactively to new technologies and patients are empowered to take control over their data, for example. We identified initiatives that can be started now to achieve our vision. Pharmaceutical companies, academic researchers, non-governmental organizations (including patient organizations), regulatory authorities, policymakers, technology companies and innovative service providers must join forces and work on initiatives to integrate technology into trials, enable data sharing, harmonize regulations across regions, co-design trials with patients and caregivers, strengthen decentralized trial capabilities and promote diversity in trials.

Conclusion: Through a collaborative cross-industry effort that prioritizes proactive patient involvement and responsible use of technology, we can shape a clinical trial ecosystem that is inclusive, ethical and ready for the future. We urge all stakeholders to act now on these initiatives to positively influence the future of clinical trials.

通过战略远见塑造临床试验的未来。
背景/目标:包括人口增长、互联互通和人工智能在内的全球大趋势已经在塑造临床试验行业,并将在未来几十年继续这样做。来自科技公司的创新,与患者和护理人员的更大合作,以及临床试验的多样性增加,可能会改变未来的临床试验。然而,该行业采用新技术的速度通常很慢,某些障碍可能会扼杀创新,使卫生不平等现象持续存在。我们的目标是探索影响临床试验的趋势,并确定现在可以开始的举措,以迈向患者积极参与临床试验设计和决策的未来,并将人工智能等技术负责任地和合乎道德地纳入临床试验。方法:我们使用战略预见方法来探索将塑造临床试验未来的趋势,以及这些趋势的轨迹如何导致不同的未来情景。然后,我们确定了可以帮助我们朝着我们期望的情景前进的举措。结果:基于数据共享和监管框架的适应这两个关键趋势,我们确定了未来临床试验的四种可能情况。虽然未来将从不同来源收集大量数据,如数据库和可穿戴设备,但如果数据仍然存在孤岛,受到严格法规和对数据隐私缺乏信任的限制,它们的用处可能会受到限制。或者,如果监管机构主动适应新技术,并且赋予患者控制其数据的权力,数据可能更有效地整合到临床试验中。我们确定了现在可以开始的举措,以实现我们的愿景。制药公司、学术研究人员、非政府组织(包括患者组织)、监管机构、政策制定者、技术公司和创新服务提供者必须联合起来,制定各项举措,将技术纳入试验,实现数据共享,协调各地区的法规,与患者和护理人员共同设计试验,加强分散的试验能力,促进试验的多样性。结论:通过跨行业合作,优先考虑患者的主动参与和负责任地使用技术,我们可以塑造一个包容、合乎道德并为未来做好准备的临床试验生态系统。我们敦促所有利益攸关方现在就这些举措采取行动,以积极影响临床试验的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Trials
Clinical Trials 医学-医学:研究与实验
CiteScore
4.10
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书